Ceftibuten

Cephalosporin Antibacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Ceftibuten is an ofm drug in the Cephalosporin Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 1995. DrugCentral lists 3 molecular targets, including Penicillin-binding protein, pbp3 and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB. Recorded indications include Acute bacterial bronchitis, Acute otitis media, Haemophilus Influenzae Acute Otitis Media and Haemophilus Influenzae Chronic Bronchitis.

• Approval status: ofm (first approved 1995 by the FDA).
• Drug class: Cephalosporin Antibacterial.
• Molecular targets: Penicillin-binding protein, pbp3 and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB (3 listed in DrugCentral).
• Indications: Acute bacterial bronchitis, Acute otitis media, Haemophilus Influenzae Acute Otitis Media, Haemophilus Influenzae Chronic Bronchitis and Infective otitis media and others.
• ATC code: J01DD14 (Third-generation cephalosporins).
• Molecular formula: C15H14N4O6S2; molecular weight 410.42 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (11)

• Acute bacterial bronchitis
• Acute otitis media
• Haemophilus Influenzae Acute Otitis Media
• Haemophilus Influenzae Chronic Bronchitis
• Infective otitis media
• Moraxella Catarrhalis Acute Otitis Media
• Moraxella Catarrhalis Chronic Bronchitis
• Streptococcal tonsillitis
• Streptococcus Pneumoniae Chronic Bronchitis
• Streptococcus pyogenes infection
• Tonsillitis

Contraindications (3)

• Colitis
• Impaired renal function disorder
• Pseudomembranous enterocolitis

Mechanism & targets

• Established pharmacologic class: Cephalosporin Antibacterial

Molecular targets (3)

Target	Gene	Action	Activity
Penicillin-binding protein	—	unknown	—
Penicillin-binding protein 3	pbp3	unknown	—
Bacterial penicillin-binding protein	mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1995-12-20	FDA	—	PERNIX THERAP

ATC classification

ATC code	Therapeutic hierarchy
J01DD14	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Third-generation cephalosporins

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ceftibuten is on its molecule page.

• Molecular formula: C₁₅H₁₄N₄O₆S₂
• Molecular weight: 410.42 g/mol
• CAS number: 97519-39-6
• InChIKey: UNJFKXSSGBWRBZ-BJCIPQKHSA-N
• PubChem CID: 5282242

NC1=NC(=CS1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ceftibuten used for?

DrugCentral lists the following indications for Ceftibuten: Acute bacterial bronchitis, Acute otitis media, Haemophilus Influenzae Acute Otitis Media, Haemophilus Influenzae Chronic Bronchitis, Infective otitis media, Moraxella Catarrhalis Acute Otitis Media, Moraxella Catarrhalis Chronic Bronchitis and Streptococcal tonsillitis and others.

How does Ceftibuten work?

Its molecular targets in DrugCentral include Penicillin-binding protein, pbp3 and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB (inhibitor).

When was Ceftibuten first approved?

Ceftibuten was first approved by the FDA in 1995.

What drug class does Ceftibuten belong to?

Ceftibuten is in the Cephalosporin Antibacterial class.

What is the chemical formula of Ceftibuten?

Ceftibuten has the molecular formula C15H14N4O6S2 and a molecular weight of 410.42 g/mol.

Sources

• DrugCentral drug card 562 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200985 — compound record and bioactivity
• PubChem CID 5282242 — chemical identifiers
• DrugBank DB01415 — drug record
• FDA UNII IW71N46B4Y — substance identity
• DailyMed: FDA labels for Ceftibuten — current prescribing information (label search)

How this page is built: methodology · editorial policy & corrections.